organization · Reporting owner
SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ACHILLION PHARMACEUTICALS INC
Report date January 28, 2020 · Filed January 30, 2020
Jointly reported with G1 EXECUTION SERVICES, LLC, SUSQUEHANNA SECURITIES, LLC
Section 16 reporting ended · disclosed 2020-01-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-01-28 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2020-01-28 · Other · Disposed 10,917 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger among Achillion Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc. and Beagle Merger Sub, Inc. In addition to the cash consideration of $6.30 per share, each shareholder will also receive one contingent value right ("CVR") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471. F2: These securities are directly owned by G1 Execution Services, LLC ("G1X"). F4: G1X, Susquehanna Fundamental Investments, LLC ("SFNDI") and SS are affiliated entities under common ownership. G1X, SFNDI and SS each disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interest therein, and this report shall not be deemed an admission that any of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-01-28 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2020-01-28 · Other · Disposed 14,115,498 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger among Achillion Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc. and Beagle Merger Sub, Inc. In addition to the cash consideration of $6.30 per share, each shareholder will also receive one contingent value right ("CVR") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471. F3: These securities are directly owned by Susquehanna Securities, LLC ("SS"). F4: G1X, Susquehanna Fundamental Investments, LLC ("SFNDI") and SS are affiliated entities under common ownership. G1X, SFNDI and SS each disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interest therein, and this report shall not be deemed an admission that any of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to an Agreement and Plan of Merger among Achillion Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc. and Beagle Merger Sub, Inc. In addition to the cash consideration of $6.30 per share, each shareholder will also receive one contingent value right ("CVR") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471.
F2: These securities are directly owned by G1 Execution Services, LLC ("G1X").
F3: These securities are directly owned by Susquehanna Securities, LLC ("SS").
F4: G1X, Susquehanna Fundamental Investments, LLC ("SFNDI") and SS are affiliated entities under common ownership. G1X, SFNDI and SS each disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interest therein, and this report shall not be deemed an admission that any of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 28, 2020 Filed Jan 30, 2020 17:15 UTC | ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234 | OtherCommon Stock | 14,115,498 | $6.30 | $88,927,637.40 |
DisclosureSEC source: 0001104659-20-008815 · a4.xml · nonDerivative · entry 2 G1 EXECUTION SERVICES, LLC · CIK 0001136305 · 10% owner SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC · CIK 0001446179 · 10% owner SUSQUEHANNA SECURITIES, LLC · CIK 0001446580 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Disposed of pursuant to an Agreement and Plan of Merger among Achillion Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc. and Beagle Merger Sub, Inc. In addition to the cash consideration of $6.30 per share, each shareholder will also receive one contingent value right ("CVR") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471. F1 · price: Disposed of pursuant to an Agreement and Plan of Merger among Achillion Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc. and Beagle Merger Sub, Inc. In addition to the cash consideration of $6.30 per share, each shareholder will also receive one contingent value right ("CVR") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471. F3 · ownership.direct: These securities are directly owned by Susquehanna Securities, LLC ("SS"). F4 · ownership.direct: G1X, Susquehanna Fundamental Investments, LLC ("SFNDI") and SS are affiliated entities under common ownership. G1X, SFNDI and SS each disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interest therein, and this report shall not be deemed an admission that any of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| January 28, 2020 Filed Jan 30, 2020 17:15 UTC | ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234 | OtherCommon Stock | 10,917 | $6.30 | $68,777.10 |
DisclosureSEC source: 0001104659-20-008815 · a4.xml · nonDerivative · entry 1 G1 EXECUTION SERVICES, LLC · CIK 0001136305 · 10% owner SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC · CIK 0001446179 · 10% owner SUSQUEHANNA SECURITIES, LLC · CIK 0001446580 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Disposed of pursuant to an Agreement and Plan of Merger among Achillion Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc. and Beagle Merger Sub, Inc. In addition to the cash consideration of $6.30 per share, each shareholder will also receive one contingent value right ("CVR") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471. F1 · price: Disposed of pursuant to an Agreement and Plan of Merger among Achillion Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc. and Beagle Merger Sub, Inc. In addition to the cash consideration of $6.30 per share, each shareholder will also receive one contingent value right ("CVR") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471. F2 · ownership.direct: These securities are directly owned by G1 Execution Services, LLC ("G1X"). F4 · ownership.direct: G1X, Susquehanna Fundamental Investments, LLC ("SFNDI") and SS are affiliated entities under common ownership. G1X, SFNDI and SS each disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interest therein, and this report shall not be deemed an admission that any of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.